Corpus
PascalFrancis
Racine
Corpus
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Serotonin and Parkinson's Disease: On Movement, Mood, and Madness

Identifieur interne : 000525 ( PascalFrancis/Corpus ); précédent : 000524; suivant : 000526

Serotonin and Parkinson's Disease: On Movement, Mood, and Madness

Auteurs : Susan H. Fox ; Rosalind Chuang ; Jonathan M. Brotchie

Source :

RBID : Pascal:09-0349961

Descripteurs français

English descriptors

Abstract

An appreciation of the multiple roles that serotonin (5-HT) may play in Parkinson's disease (PD) has increased in recent years. Early pathological studies in PD demonstrated nonselective reductions of 5-HT in brain tissue but little correlation to comorbidities such as dyskinesia and mood disturbance. This, combined with treatment failures using serotonergic drugs in comparison to levodopa, meant the field was largely neglected until recently. The multitude of subtypes of 5-HT receptors in the brain and an increased understanding of the potential function 5-HT may play in modulating other neurotransmitter systems, including dopamine, GABA, and glutamate, have meant an expansion in efforts to develop potential serotonergic drugs for both motor and nonmotor symptoms in PD. However, several unanswered questions remain, and future studies need to focus on correlating changes in 5-HT neurotransmission in both pathological and in vivo imaging studies with a full clinical phenotype.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

pA  
A01 01  1    @0 0885-3185
A03   1    @0 Mov. disord.
A05       @2 24
A06       @2 9
A08 01  1  ENG  @1 Serotonin and Parkinson's Disease: On Movement, Mood, and Madness
A11 01  1    @1 FOX (Susan H.)
A11 02  1    @1 CHUANG (Rosalind)
A11 03  1    @1 BROTCHIE (Jonathan M.)
A14 01      @1 Movement Disorders Clinic, McL 7-121, University of Toronto, Toronto Western Hospital @2 Toronto, Ontario @3 CAN @Z 1 aut. @Z 2 aut.
A14 02      @1 Division of Brain, Imaging and Behavior - Systems Neuroscience, Toronto Western Research Institute @2 Toronto, Ontario @3 CAN @Z 3 aut.
A20       @1 1255-1266
A21       @1 2009
A23 01      @0 ENG
A43 01      @1 INIST @2 20953 @5 354000170902500010
A44       @0 0000 @1 © 2009 INIST-CNRS. All rights reserved.
A45       @0 151 ref.
A47 01  1    @0 09-0349961
A60       @1 P
A61       @0 A
A64 01  1    @0 Movement disorders
A66 01      @0 USA
C01 01    ENG  @0 An appreciation of the multiple roles that serotonin (5-HT) may play in Parkinson's disease (PD) has increased in recent years. Early pathological studies in PD demonstrated nonselective reductions of 5-HT in brain tissue but little correlation to comorbidities such as dyskinesia and mood disturbance. This, combined with treatment failures using serotonergic drugs in comparison to levodopa, meant the field was largely neglected until recently. The multitude of subtypes of 5-HT receptors in the brain and an increased understanding of the potential function 5-HT may play in modulating other neurotransmitter systems, including dopamine, GABA, and glutamate, have meant an expansion in efforts to develop potential serotonergic drugs for both motor and nonmotor symptoms in PD. However, several unanswered questions remain, and future studies need to focus on correlating changes in 5-HT neurotransmission in both pathological and in vivo imaging studies with a full clinical phenotype.
C02 01  X    @0 002B17
C02 02  X    @0 002B17G
C03 01  X  FRE  @0 Maladie de Parkinson @2 NM @5 01
C03 01  X  ENG  @0 Parkinson disease @2 NM @5 01
C03 01  X  SPA  @0 Parkinson enfermedad @2 NM @5 01
C03 02  X  FRE  @0 Dyskinésie @5 02
C03 02  X  ENG  @0 Dyskinesia @5 02
C03 02  X  SPA  @0 Disquinesia @5 02
C03 03  X  FRE  @0 Etat dépressif @5 03
C03 03  X  ENG  @0 Depression @5 03
C03 03  X  SPA  @0 Estado depresivo @5 03
C03 04  X  FRE  @0 Angoisse anxiété @5 04
C03 04  X  ENG  @0 Anxiety @5 04
C03 04  X  SPA  @0 Angustia ansiedad @5 04
C03 05  X  FRE  @0 Psychose @5 05
C03 05  X  ENG  @0 Psychosis @5 05
C03 05  X  SPA  @0 Psicosis @5 05
C03 06  X  FRE  @0 Constipation @5 06
C03 06  X  ENG  @0 Constipation @5 06
C03 06  X  SPA  @0 Constipación @5 06
C03 07  X  FRE  @0 Pathologie du système nerveux @5 07
C03 07  X  ENG  @0 Nervous system diseases @5 07
C03 07  X  SPA  @0 Sistema nervioso patología @5 07
C03 08  X  FRE  @0 Sérotonine @2 NK @2 FR @5 09
C03 08  X  ENG  @0 Serotonin @2 NK @2 FR @5 09
C03 08  X  SPA  @0 Serotonina @2 NK @2 FR @5 09
C03 09  X  FRE  @0 Humeur @5 10
C03 09  X  ENG  @0 Mood @5 10
C03 09  X  SPA  @0 Humor @5 10
C07 01  X  FRE  @0 Neurotransmetteur @5 37
C07 01  X  ENG  @0 Neurotransmitter @5 37
C07 01  X  SPA  @0 Neurotransmisor @5 37
C07 02  X  FRE  @0 Pathologie de l'encéphale @5 38
C07 02  X  ENG  @0 Cerebral disorder @5 38
C07 02  X  SPA  @0 Encéfalo patología @5 38
C07 03  X  FRE  @0 Syndrome extrapyramidal @5 39
C07 03  X  ENG  @0 Extrapyramidal syndrome @5 39
C07 03  X  SPA  @0 Extrapiramidal síndrome @5 39
C07 04  X  FRE  @0 Maladie dégénérative @5 40
C07 04  X  ENG  @0 Degenerative disease @5 40
C07 04  X  SPA  @0 Enfermedad degenerativa @5 40
C07 05  X  FRE  @0 Pathologie du système nerveux central @5 41
C07 05  X  ENG  @0 Central nervous system disease @5 41
C07 05  X  SPA  @0 Sistema nervosio central patología @5 41
C07 06  X  FRE  @0 Mouvement involontaire @5 43
C07 06  X  ENG  @0 Involuntary movement @5 43
C07 06  X  SPA  @0 Movimiento involuntario @5 43
C07 07  X  FRE  @0 Trouble neurologique @5 44
C07 07  X  ENG  @0 Neurological disorder @5 44
C07 07  X  SPA  @0 Trastorno neurológico @5 44
C07 08  X  FRE  @0 Trouble de l'humeur @5 45
C07 08  X  ENG  @0 Mood disorder @5 45
C07 08  X  SPA  @0 Trastorno humor @5 45
C07 09  X  FRE  @0 Affect affectivité @5 46
C07 09  X  ENG  @0 Affect affectivity @5 46
C07 09  X  SPA  @0 Afecto afectividad @5 46
C07 10  X  FRE  @0 Pathologie de l'appareil digestif @5 47
C07 10  X  ENG  @0 Digestive diseases @5 47
C07 10  X  SPA  @0 Aparato digestivo patología @5 47
C07 11  X  FRE  @0 Pathologie de l'intestin @5 48
C07 11  X  ENG  @0 Intestinal disease @5 48
C07 11  X  SPA  @0 Intestino patología @5 48
N21       @1 257
N44 01      @1 OTO
N82       @1 OTO

Format Inist (serveur)

NO : PASCAL 09-0349961 INIST
ET : Serotonin and Parkinson's Disease: On Movement, Mood, and Madness
AU : FOX (Susan H.); CHUANG (Rosalind); BROTCHIE (Jonathan M.)
AF : Movement Disorders Clinic, McL 7-121, University of Toronto, Toronto Western Hospital/Toronto, Ontario/Canada (1 aut., 2 aut.); Division of Brain, Imaging and Behavior - Systems Neuroscience, Toronto Western Research Institute/Toronto, Ontario/Canada (3 aut.)
DT : Publication en série; Niveau analytique
SO : Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 9; Pp. 1255-1266; Bibl. 151 ref.
LA : Anglais
EA : An appreciation of the multiple roles that serotonin (5-HT) may play in Parkinson's disease (PD) has increased in recent years. Early pathological studies in PD demonstrated nonselective reductions of 5-HT in brain tissue but little correlation to comorbidities such as dyskinesia and mood disturbance. This, combined with treatment failures using serotonergic drugs in comparison to levodopa, meant the field was largely neglected until recently. The multitude of subtypes of 5-HT receptors in the brain and an increased understanding of the potential function 5-HT may play in modulating other neurotransmitter systems, including dopamine, GABA, and glutamate, have meant an expansion in efforts to develop potential serotonergic drugs for both motor and nonmotor symptoms in PD. However, several unanswered questions remain, and future studies need to focus on correlating changes in 5-HT neurotransmission in both pathological and in vivo imaging studies with a full clinical phenotype.
CC : 002B17; 002B17G
FD : Maladie de Parkinson; Dyskinésie; Etat dépressif; Angoisse anxiété; Psychose; Constipation; Pathologie du système nerveux; Sérotonine; Humeur
FG : Neurotransmetteur; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central; Mouvement involontaire; Trouble neurologique; Trouble de l'humeur; Affect affectivité; Pathologie de l'appareil digestif; Pathologie de l'intestin
ED : Parkinson disease; Dyskinesia; Depression; Anxiety; Psychosis; Constipation; Nervous system diseases; Serotonin; Mood
EG : Neurotransmitter; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Involuntary movement; Neurological disorder; Mood disorder; Affect affectivity; Digestive diseases; Intestinal disease
SD : Parkinson enfermedad; Disquinesia; Estado depresivo; Angustia ansiedad; Psicosis; Constipación; Sistema nervioso patología; Serotonina; Humor
LO : INIST-20953.354000170902500010
ID : 09-0349961

Links to Exploration step

Pascal:09-0349961

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Serotonin and Parkinson's Disease: On Movement, Mood, and Madness</title>
<author>
<name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Movement Disorders Clinic, McL 7-121, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Chuang, Rosalind" sort="Chuang, Rosalind" uniqKey="Chuang R" first="Rosalind" last="Chuang">Rosalind Chuang</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Movement Disorders Clinic, McL 7-121, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Division of Brain, Imaging and Behavior - Systems Neuroscience, Toronto Western Research Institute</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">09-0349961</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0349961 INIST</idno>
<idno type="RBID">Pascal:09-0349961</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000525</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Serotonin and Parkinson's Disease: On Movement, Mood, and Madness</title>
<author>
<name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Movement Disorders Clinic, McL 7-121, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Chuang, Rosalind" sort="Chuang, Rosalind" uniqKey="Chuang R" first="Rosalind" last="Chuang">Rosalind Chuang</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Movement Disorders Clinic, McL 7-121, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Division of Brain, Imaging and Behavior - Systems Neuroscience, Toronto Western Research Institute</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Anxiety</term>
<term>Constipation</term>
<term>Depression</term>
<term>Dyskinesia</term>
<term>Mood</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Psychosis</term>
<term>Serotonin</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Maladie de Parkinson</term>
<term>Dyskinésie</term>
<term>Etat dépressif</term>
<term>Angoisse anxiété</term>
<term>Psychose</term>
<term>Constipation</term>
<term>Pathologie du système nerveux</term>
<term>Sérotonine</term>
<term>Humeur</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">An appreciation of the multiple roles that serotonin (5-HT) may play in Parkinson's disease (PD) has increased in recent years. Early pathological studies in PD demonstrated nonselective reductions of 5-HT in brain tissue but little correlation to comorbidities such as dyskinesia and mood disturbance. This, combined with treatment failures using serotonergic drugs in comparison to levodopa, meant the field was largely neglected until recently. The multitude of subtypes of 5-HT receptors in the brain and an increased understanding of the potential function 5-HT may play in modulating other neurotransmitter systems, including dopamine, GABA, and glutamate, have meant an expansion in efforts to develop potential serotonergic drugs for both motor and nonmotor symptoms in PD. However, several unanswered questions remain, and future studies need to focus on correlating changes in 5-HT neurotransmission in both pathological and in vivo imaging studies with a full clinical phenotype.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0885-3185</s0>
</fA01>
<fA03 i2="1">
<s0>Mov. disord.</s0>
</fA03>
<fA05>
<s2>24</s2>
</fA05>
<fA06>
<s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Serotonin and Parkinson's Disease: On Movement, Mood, and Madness</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>FOX (Susan H.)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>CHUANG (Rosalind)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>BROTCHIE (Jonathan M.)</s1>
</fA11>
<fA14 i1="01">
<s1>Movement Disorders Clinic, McL 7-121, University of Toronto, Toronto Western Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Division of Brain, Imaging and Behavior - Systems Neuroscience, Toronto Western Research Institute</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20>
<s1>1255-1266</s1>
</fA20>
<fA21>
<s1>2009</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>20953</s2>
<s5>354000170902500010</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>151 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>09-0349961</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Movement disorders</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>An appreciation of the multiple roles that serotonin (5-HT) may play in Parkinson's disease (PD) has increased in recent years. Early pathological studies in PD demonstrated nonselective reductions of 5-HT in brain tissue but little correlation to comorbidities such as dyskinesia and mood disturbance. This, combined with treatment failures using serotonergic drugs in comparison to levodopa, meant the field was largely neglected until recently. The multitude of subtypes of 5-HT receptors in the brain and an increased understanding of the potential function 5-HT may play in modulating other neurotransmitter systems, including dopamine, GABA, and glutamate, have meant an expansion in efforts to develop potential serotonergic drugs for both motor and nonmotor symptoms in PD. However, several unanswered questions remain, and future studies need to focus on correlating changes in 5-HT neurotransmission in both pathological and in vivo imaging studies with a full clinical phenotype.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Dyskinésie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Dyskinesia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Disquinesia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Etat dépressif</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Depression</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Estado depresivo</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Angoisse anxiété</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Anxiety</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Angustia ansiedad</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Psychose</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Psychosis</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Psicosis</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Constipation</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Constipation</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Constipación</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Pathologie du système nerveux</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Sérotonine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Serotonin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Serotonina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Humeur</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Mood</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Humor</s0>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Neurotransmetteur</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Neurotransmitter</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Neurotransmisor</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Pathologie de l'encéphale</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Syndrome extrapyramidal</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Pathologie du système nerveux central</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Mouvement involontaire</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Involuntary movement</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Movimiento involuntario</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Trouble neurologique</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>Neurological disorder</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Trastorno neurológico</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE">
<s0>Trouble de l'humeur</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG">
<s0>Mood disorder</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA">
<s0>Trastorno humor</s0>
<s5>45</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE">
<s0>Affect affectivité</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG">
<s0>Affect affectivity</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA">
<s0>Afecto afectividad</s0>
<s5>46</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE">
<s0>Pathologie de l'appareil digestif</s0>
<s5>47</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG">
<s0>Digestive diseases</s0>
<s5>47</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA">
<s0>Aparato digestivo patología</s0>
<s5>47</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE">
<s0>Pathologie de l'intestin</s0>
<s5>48</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG">
<s0>Intestinal disease</s0>
<s5>48</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA">
<s0>Intestino patología</s0>
<s5>48</s5>
</fC07>
<fN21>
<s1>257</s1>
</fN21>
<fN44 i1="01">
<s1>OTO</s1>
</fN44>
<fN82>
<s1>OTO</s1>
</fN82>
</pA>
</standard>
<server>
<NO>PASCAL 09-0349961 INIST</NO>
<ET>Serotonin and Parkinson's Disease: On Movement, Mood, and Madness</ET>
<AU>FOX (Susan H.); CHUANG (Rosalind); BROTCHIE (Jonathan M.)</AU>
<AF>Movement Disorders Clinic, McL 7-121, University of Toronto, Toronto Western Hospital/Toronto, Ontario/Canada (1 aut., 2 aut.); Division of Brain, Imaging and Behavior - Systems Neuroscience, Toronto Western Research Institute/Toronto, Ontario/Canada (3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2009; Vol. 24; No. 9; Pp. 1255-1266; Bibl. 151 ref.</SO>
<LA>Anglais</LA>
<EA>An appreciation of the multiple roles that serotonin (5-HT) may play in Parkinson's disease (PD) has increased in recent years. Early pathological studies in PD demonstrated nonselective reductions of 5-HT in brain tissue but little correlation to comorbidities such as dyskinesia and mood disturbance. This, combined with treatment failures using serotonergic drugs in comparison to levodopa, meant the field was largely neglected until recently. The multitude of subtypes of 5-HT receptors in the brain and an increased understanding of the potential function 5-HT may play in modulating other neurotransmitter systems, including dopamine, GABA, and glutamate, have meant an expansion in efforts to develop potential serotonergic drugs for both motor and nonmotor symptoms in PD. However, several unanswered questions remain, and future studies need to focus on correlating changes in 5-HT neurotransmission in both pathological and in vivo imaging studies with a full clinical phenotype.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Dyskinésie; Etat dépressif; Angoisse anxiété; Psychose; Constipation; Pathologie du système nerveux; Sérotonine; Humeur</FD>
<FG>Neurotransmetteur; Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central; Mouvement involontaire; Trouble neurologique; Trouble de l'humeur; Affect affectivité; Pathologie de l'appareil digestif; Pathologie de l'intestin</FG>
<ED>Parkinson disease; Dyskinesia; Depression; Anxiety; Psychosis; Constipation; Nervous system diseases; Serotonin; Mood</ED>
<EG>Neurotransmitter; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Involuntary movement; Neurological disorder; Mood disorder; Affect affectivity; Digestive diseases; Intestinal disease</EG>
<SD>Parkinson enfermedad; Disquinesia; Estado depresivo; Angustia ansiedad; Psicosis; Constipación; Sistema nervioso patología; Serotonina; Humor</SD>
<LO>INIST-20953.354000170902500010</LO>
<ID>09-0349961</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000525 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000525 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:09-0349961
   |texte=   Serotonin and Parkinson's Disease: On Movement, Mood, and Madness
}}
Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022